TROP2 overexpression associated with decreased overall survival (p< 0.01), presence of lymph node metastasis (p = 0.04), tumor grade (p = 0.01), and poor progression-free survival after surgery (p < 0.01). The gene discussed is TACSTD2; the disease is metastatic malignant neoplasm in the lymph nodes.